Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) (NCT06170788)
A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic in Arizona - Phoenix ( Site 0147) — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (220 Sites)
Showing the first 25 of 220 sites.
- Mayo Clinic in Arizona - Phoenix ( Site 0147) — Phoenix, Arizona
- Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0130) — Burbank, California
- Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0132) — Grand Junction, Colorado
- Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0133) — Jacksonville, Florida
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0106) — Marietta, Georgia
- The University of Louisville, James Graham Brown Cancer Center ( Site 0121) — Louisville, Kentucky
- New England Cancer Specialists ( Site 0143) — Westbrook, Maine
- University of Massachusetts Chan Medical School-Division of Hematology/Oncology ( Site 0144) — Worcester, Massachusetts
- Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0115) — Minneapolis, Minnesota
- Mayo Clinic - Rochester ( Site 0148) — Rochester, Minnesota
- Hattiesburg Clinic Hematology/Oncology ( Site 0104) — Hattiesburg, Mississippi
- Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0134) — Reno, Nevada
- University Hospitals Cleveland Medical Center ( Site 0119) — Cleveland, Ohio
- Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0117) — Corvallis, Oregon
- Oncology Consultants P.A. ( Site 0129) — Houston, Texas
- Instituto Alexander Fleming ( Site 0306) — Ciudad Autónoma de Buenos Aires, Buenos Aires
- Hospital Británico de Buenos Aires-Oncology ( Site 0304) — Buenos Aires, Buenos Aires F.D.
- Centro Privado de RMI Río Cuarto S.A. II ( Site 0310) — Río Cuarto, Córdoba Province
- Instituto de Oncología de Rosario ( Site 0301) — Rosario, Santa Fe Province
- Hospital Aleman-Oncology ( Site 0300) — Buenos Aires,
- Port Macquarie - Mid North Coast Cancer Institute-Medical Oncology ( Site 3002) — Port Macquarie, New South Wales
- Westmead Hospital ( Site 3000) — Westmead, New South Wales
- Grampians Health-Medical Oncology ( Site 3001) — Ballarat Central, Victoria
- Northern Hospital ( Site 3003) — Epping, Victoria
- Peninsula University Hospital ( Site 3004) — Frankston, Victoria
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-small Cell Lung Cancer (NSCLC)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) — Oakland, California
- HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer — Santa Monica, California
- PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung — Tampa, Florida
- U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer — Duarte, California
- Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC — Duarte, California
- Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) — Birmingham, Alabama
Explore by condition: All Non-small Cell Lung Cancer (NSCLC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.